SEED
Intellectual Property Law Group PLLC

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

Carol D. Laherty, Ph.D., J.D.
caroll@seedlaw.com

July 7, 2003

Facsimile Transmission

3 pages including this page

TO: Examiner Carla J. Meyers
Fax No.: (703) 746-5042
Phone No.: (703) 308-2199

RE: U.S. Patent Application No. 09/658,824
COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
Our Reference: 210121.478C11

☐ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP

Comments:

Per your request, please see attached Declaration of Gary D. Fanger (referenced in and filed with Applicants' Amendment Under 37 C.F.R. § 1.111 on June 17, 2003).

Please let us know if we can be of any further assistance.

Sandi Duncan
Legal Assistant to Carol D. Laherty, Ph.D.

If you do not receive all pages, please call Sandi Duncan at (206) 622-4900 or fax our office.

Transmission Information: Date _____ Time _____ By _____

EXPRESS MAIL NO.
EV207743635US

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D. C. 20231.
Date:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Wang, et al.
Application No.	:	09/614,124 for application 09/658,824
Filed	:	July 11, 2000
For	:	COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF LUNG CANCER
Examiner		Michael Borin
Art Unit		1631
Docket No.		210121.478C9
Date		February 8, 2002

DECLARATION OF GARY FANGER, PH.D.

Assistant Commissioner of Patents
Washington D.C. 20231

The undersigned, Gary Fanger, Ph.D., hereby declares:

1. I am a Scientist and Project Group Leader at Corixa Corporation, the assignee of the subject application. The following experiments were performed under my supervision.

2. In order to confirm L552S protein expression in various normal lung and lung cancer tissues, immunohistochemistry (IHC) analysis was performed using an affinity purified L552S polyclonal antibody. Specifically, tissue samples were fixed in a formalin solution for 12-24 hrs and embedded in paraffin before being sliced into 8 micron sections. Steam heat induced epitope retrieval (SHIER) in 0.1 M sodium citrate buffer (pH 6.0) was used for optimal staining conditions. Sections were incubated with 10% serum/PBS for 5 minutes. Primary antibody was added to each section for 25

minutes at indicated concentrations followed by a 25 minute incubation with an anti-rabbit biotinylated antibody. Endogenous peroxidase activity was blocked by three-1.5 minute incubations with hydrogen peroxidase. The avidin biotin complex/horse radish peroxidase (ABC/HRP) system was used along with DAB chromogen to visualize L552S expression. Slides were counterstained with hematoxylin to visualize cell nuclei. L552S polypeptide expression was detected in 10/12 lung adenocarcinoma samples, whereas no expression was detected in 13 normal lung samples evaluated. This expression pattern supports the use of L552S polypeptide as a cancer diagnostic marker.

3. The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful, false statements, and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Gary Fanger, Ph.D.

2/28/02
Date

D:\NrPortbl\iManage\BOBF\249588_1.DOC